This policy brief provides a summary of a recent review of the definition of rare diseases, high cost and how HTA has been used in the case of rare diseases in seven countries. The countries were purposively selected based on them having established HTA policies and availability of resources in the

There is a growing demand for public health insurance programmes to reimburse high-cost medicines, including those that do not represent good value-for-money. This demand is likely to inhibit financial sustainability, given the growth of new technologies and public demands for expanded access to car

There is a growing demand for public health insurance programmes to reimburse high-cost medicines, including those that do not represent good value-for-money. This demand is likely to inhibit financial sustainability, given the growth of new technologies and public demands for expanded access to car

Yot Teerawattananon,1 Sripen Tantivess,1 Pitsaphun Werayingyong,1 Pritaporn Kingkaew,1 Nilar Tin,2 San San Aye,3 Phone Myint3 Abstract Introduction: In 2010, with financial support from the Global Alliance for Vaccine and Immunization’s Health System Strengthening programme, the Government of

Evidence-Based Decision-Making in Asia-Pacific with Rapidly Changing Health-Care Systems: Thailand, South Korea, and Taiwan. Thidaporn Jirawattanapisal1 Pritaporn Kingkaew2 Tae-Jin Lee3 Ming-Chin Yang4 1International Health Policy Program, Ministry of Public Health, Muang Nonthaburi,Thailand; 2

17-2-021-2559(2)

Generic reference cases for economic evaluation (EE) of “cure-based” health technologies may not fit into the new healthcare paradigm of precision medicine (PM). Current EE approaches were challenged by the complex evolving decision space of PM, lack of clinical evidence due to small patient cluster

(Reuters) – Europe’s medicines regulator, criticised in the past for excessive secrecy, is opening its data vaults to systematic scrutiny in a move that will let independent researchers trawl through millions of pages of clinical trial information.The change is a landmark in transparency that puts E

Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter? Thavorncharoensap M1, Teerawattananon Y, Natanant S, Kulpeng W, Yothasamut J, Werayingyong P 1Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Thailand ; Heal